Clinical Report: Hepatotoxicity Associated with Ribociclib in Breast Cancer Patients
Overview
This multi-center analysis identifies hepatotoxicity as a significant adverse event in breast cancer patients treated with ribociclib, with 9.2% of patients developing liver injury. The study highlights the need for careful monitoring and management of liver function in this patient population.
Background
Ribociclib, a CDK4/6 inhibitor, has shown efficacy in treating hormone receptor-positive, HER2-negative breast cancer. However, its hepatic metabolism raises concerns about potential hepatotoxicity, which can complicate treatment. Understanding the incidence and management of this adverse effect is crucial for optimizing patient outcomes.
Data Highlights
{'Grade 4 Hepatotoxicity': '5 (6.4% of 78)'}
Key Findings
{'Grade 4 Hepatotoxicity': '5 patients (6.4% of those with hepatotoxicity)'}
Clinical Implications
{'recommendation': 'Implement liver function tests every 2-4 weeks during initial treatment cycles.'}
Conclusion
{'add': 'Examples of management strategies should be included.'}
by Onur Baş, Bediz Kurt İnci, İmdat Eroğlu, Safa Can Efil, Seher Kaya, Pınar Kubilay Tolunay, Taha Koray Şahin, Cengiz Karaçin, Ozan Yazıcı, Mehmet Ali Nahit Şendur, Berna Ömür Çakmak Öksüzoğlu, Sercan Aksoy
